253 related articles for article (PubMed ID: 27027662)
41. Glucagon - the new 'insulin' in the pathophysiology of diabetes.
Farhy LS; McCall AL
Curr Opin Clin Nutr Metab Care; 2015 Jul; 18(4):407-14. PubMed ID: 26049639
[TBL] [Abstract][Full Text] [Related]
42. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.
Shah P; Vella A; Basu A; Basu R; Schwenk WF; Rizza RA
J Clin Endocrinol Metab; 2000 Nov; 85(11):4053-9. PubMed ID: 11095432
[TBL] [Abstract][Full Text] [Related]
43. A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1.
Egom EE
Ther Adv Cardiovasc Dis; 2012 Oct; 6(5):213-9. PubMed ID: 22902834
[TBL] [Abstract][Full Text] [Related]
44. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
45. [Hyperglycemia and its control in the critically ill patient].
Kotulák T; Ríha H; Haluzík M
Cas Lek Cesk; 2011; 150(1):20-3. PubMed ID: 21404483
[TBL] [Abstract][Full Text] [Related]
46. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
47. The role of incretin hormones and glucagon in patients with liver disease.
Junker AE
Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
[TBL] [Abstract][Full Text] [Related]
48. [Early-morning hyperglycemia in patients with diabetes mellitus types 1 and 2].
Jasik M
Wiad Lek; 1989 Apr; 42(8):529-32. PubMed ID: 2697976
[TBL] [Abstract][Full Text] [Related]
49. Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia.
Porcellati F; Pampanelli S; Rossetti P; Busciantella Ricci N; Marzotti S; Lucidi P; Santeusanio F; Bolli GB; Fanelli CG
Diabetologia; 2007 Feb; 50(2):422-30. PubMed ID: 17160672
[TBL] [Abstract][Full Text] [Related]
50. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054
[TBL] [Abstract][Full Text] [Related]
51. Overview of Glucagon-like Peptide-1 Receptor Agonists.
Steadman L; Grant JS; Graven LJ
Home Healthc Now; 2015; 33(10):538-44. PubMed ID: 26529445
[TBL] [Abstract][Full Text] [Related]
52. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
Al Batran R; Almutairi M; Ussher JR
Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
[TBL] [Abstract][Full Text] [Related]
53. Recommendations of the GARIN group for managing non-critically ill patients with diabetes or stress hyperglycaemia and artificial nutrition.
Olveira G; García-Luna PP; Pereira JL; Rebollo I; García-Almeida JM; Serrano P; Irles JA; Muñoz-Aguilar A; Molina MJ; Tapia MJ;
Nutr Hosp; 2012; 27(6):1837-49. PubMed ID: 23588430
[TBL] [Abstract][Full Text] [Related]
54. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
Thrasher J
Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
[TBL] [Abstract][Full Text] [Related]
55. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
Baretić M; Troskot R
Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
[TBL] [Abstract][Full Text] [Related]
56. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
Darmon P; Raccah D
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
[TBL] [Abstract][Full Text] [Related]
57. Evidence That in Uncontrolled Diabetes, Hyperglucagonemia Is Required for Ketosis but Not for Increased Hepatic Glucose Production or Hyperglycemia.
Meek TH; Dorfman MD; Matsen ME; Fischer JD; Cubelo A; Kumar MR; Taborsky GJ; Morton GJ
Diabetes; 2015 Jul; 64(7):2376-87. PubMed ID: 25633417
[TBL] [Abstract][Full Text] [Related]
58. Synergistic interactions of physiologic increments of glucagon, epinephrine, and cortisol in the dog: a model for stress-induced hyperglycemia.
Eigler N; Saccà L; Sherwin RS
J Clin Invest; 1979 Jan; 63(1):114-23. PubMed ID: 762240
[TBL] [Abstract][Full Text] [Related]
59. The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes.
Hædersdal S; Lund A; Knop FK; Vilsbøll T
Mayo Clin Proc; 2018 Feb; 93(2):217-239. PubMed ID: 29307553
[TBL] [Abstract][Full Text] [Related]
60. Association of Stress-Induced Hyperglycemia and Diabetic Hyperglycemia with Mortality in Patients with Traumatic Brain Injury: Analysis of a Propensity Score-Matched Population.
Tsai YC; Wu SC; Hsieh TM; Liu HT; Huang CY; Chou SE; Su WT; Hsu SY; Hsieh CH
Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32549265
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
